TopiVert Ltd-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013473)
◆英語タイトル:TopiVert Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013473
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
TopiVert Ltd (TopiVert) is a drug development company that offers disease control solutions in inflammatory diseases of the gastrointestinal tract and the eye. The company develops and offers narrow spectrum kinase inhibitors (NSKI) for the treatment of chronic inflammatory diseases of gastrointestinal and eye. It develops various drug candidates which include TOP1288 which is intended for the treatment of ulcerative colitis, a chronic, relapsing inflammatory condition. The company also offers TOP1630, a candidate used in treatment of dry eye diseases. TopiVert is headquartered in London, the UK.

TopiVert Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
TopiVert Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
TopiVert Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
TopiVert Raises USD28 Million in Venture Financing 10
TopiVert Raises US$7.4 Million In Venture Financing 12
Topivert Raises US$12.5 Million In Venture Financing 14
Partnerships 15
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 15
Licensing Agreements 16
Topivert Enters into Licensing Agreement with RespiVert 16
TopiVert Ltd – Key Competitors 17
TopiVert Ltd – Key Employees 18
TopiVert Ltd – Locations And Subsidiaries 19
Head Office 19
Recent Developments 20
Clinical Trials 20
May 16, 2016: TopiVert completes preclinical development with TOP1630 for dry eye disease 20
May 09, 2016: TopiVert to Present First in Human Data From Its Phase I Clinical Study With TOP1288 at DDW 2016 in San Diego 21
Mar 17, 2016: TopiVert Reports Successful Phase I Study With TOP1288 for the Treatment Of Ulcerative Colitis 22
Mar 07, 2016: TopiVert to Present First-In-Human Data From Its Phase I Clinical Study With TOP1288 for the Treatment of Ulcerative Colitis at the Forthcoming 11th Congress of ECCO in Amsterdam 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
TopiVert Ltd, Pharmaceuticals & Healthcare, Key Facts 2
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
TopiVert Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
TopiVert Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
TopiVert Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
TopiVert Raises USD28 Million in Venture Financing 10
TopiVert Raises US$7.4 Million In Venture Financing 12
Topivert Raises US$12.5 Million In Venture Financing 14
Topivert Enters into Drug Discovery Collaboration Agreement with RespiVert 15
Topivert Enters into Licensing Agreement with RespiVert 16
TopiVert Ltd, Key Competitors 17
TopiVert Ltd, Key Employees 18

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ TopiVert Ltd-製薬・医療分野:企業M&A・提携分析(TopiVert Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆